A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been developed to manage type 2 diabetes mellitus. Although, in the last 10 years, the use of GLP-1 RAs, especially semaglutide and liraglutide, has increased, its clinical implications and how it affects metabolic parameters have yet to be fully consolidated. This narrative review explores the metabolic effects of GLP-1 RAs in weight management, blood glucose, cardiovascular health, lipid profiles, and blood pressure.

Managing Arrhythmias in Cardiogenic Shock: Insights Into Milrinone and Dobutamine Therapy.

Shock is a state of inadequate perfusion that affects vital organs. Cardiogenic shock (CS) predisposes patients to various arrhythmias. The adverse effect depends on intervention and pharmacogenomics.

A hybridization of XGBoost machine learning model by Optuna hyperparameter tuning suite for cardiovascular disease classification with significant effect of outliers and heterogeneous training datasets.

Background: Over the last few decades: heart disease (HD) has emerged as one of the deadliest diseases in the world. Approximately more than 31 % of the population dies from HD each year. The Diagnosis of HD in an earlier stage is a cognitively challenging task due to the vast and complex availability of medical datasets.

Characteristics of Gasless Combustion of Core-Shell Al@NiO Microparticles with Boosted Exothermic Performance.

The microstructures and thermochemical behavior of the energetic composites composed of core-shell structured μAl@NiO microparticles were characterized. These core-shell microparticles were synthesized using a wet-chemistry-based one-pot process, where the assembly was proposed to be driven by the electrostatic force between negatively charged Al and positively charged Ni-NH ions. Electron microscopic images demonstrated the formation of NiO nanoparticles adhering to the surface of microsized Al particles with different equivalence ratios.

Elongation factor 1A1 inhibition elicits changes in lipid droplet size, the bulk transcriptome, and cell type-associated gene expression in MASLD mouse liver.

Eukaryotic elongation factor 1A1 (EEF1A1), originally identified for its role in protein synthesis, has additional functions in diverse cellular processes. Of note, we previously discovered a role for EEF1A1 in hepatocyte lipotoxicity. We also demonstrated that a 2-wk intervention with the EEF1A1 inhibitor didemnin B (DB) (50 µg/kg) decreased liver steatosis in a mouse model of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) [129S6/SvEvTac mice fed Western diet (42% fat) for 26 wk].